Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 2:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 9,384 matching trials from the live ClinicalTrials.gov search.
Conditions
Asthma
Interventions
Aerovant, placebo
Drug · Other
Lead sponsor
Aerovance, Inc.
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
38
States / cities
Mobile, Alabama • Scottsdale, Arizona • Huntington Beach, California + 31 more
Conditions
Neoplasms
Interventions
Everolimus, Sandostatin LAR Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
13
States / cities
Little Rock, Arkansas • Greenwood Village, Colorado • Stamford, Connecticut + 10 more
Conditions
Leukemia
Interventions
Midostaurin (PKC412)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Augusta, Georgia + 6 more
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Avelumab, Talazoparib, Talazoparib Tosylate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
325
States / cities
Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more
Conditions
Hypoplastic Left Heart Syndrome (HLHS)
Interventions
Collaborative Learning Network
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 15 Months
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more
Conditions
Newly Diagnosed FLT3 Mutated AML
Interventions
Crenolanib, Midostaurin, Cytarabine, Duanorubicin
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
31
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 18 more
Conditions
Diabetic Macular Edema (DME)
Interventions
Ranibizumab, Remigromig
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
85
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Springdale, Arkansas + 78 more
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Conditions
CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, Laboratory Biomarker Analysis, Palbociclib
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1065
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 659 more
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Active control
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
12 Years to 18 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Age-related Macular Degeneration
Interventions
Squalamine lactate ophthalmic solution, 0.2%, Placebo Ophthalmic solution, ranibizumab
Drug
Lead sponsor
Ohr Pharmaceutical Inc.
Industry
Eligibility
50 Years to 110 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
118
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 106 more
Conditions
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cetuximab, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Survey Administration
Procedure · Drug · Biological + 2 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
150
States / cities
Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 116 more
Conditions
Ischemic Heart Disease
Interventions
Coronary artery bypass - on-pump, Coronary artery bypass - off-pump
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
2,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
17
States / cities
Palo Alto, California • San Francisco, California • Sepulveda, California + 14 more
Conditions
Small Cell Lung Cancer
Interventions
Dinutuximab, Irinotecan, Topotecan
Biological · Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
40
States / cities
Anchorage, Alaska • Goodyear, Arizona • Tucson, Arizona + 35 more
Completed No phase listed Observational

Young ESUS Patient Registry

NCT03185520
Conditions
Embolic Stroke of Undetermined Source
Interventions
Not listed
Lead sponsor
Population Health Research Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Stanford, California • Joliet, Illinois • Greensboro, North Carolina + 4 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sacituzumab Govitecan, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
16
States / cities
Mobile, Alabama • Oceanside, California • Clermont, Florida + 12 more
Conditions
Breast Cancer, Hot Flashes, Menopausal Symptoms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
flaxseed, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
107
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 71 more
Conditions
X-linked Retinoschisis
Interventions
ATSN-201
Biological
Lead sponsor
Atsena Therapeutics Inc.
Industry
Eligibility
5 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 14 more
Conditions
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Interventions
AMG 510, Docetaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
54
States / cities
Anaheim, California • Duarte, California • Long Beach, California + 46 more
Completed Phase 1Phase 2 Interventional

STA-5326 in Crohn's Disease Patients

NCT00088062
Conditions
Crohn's Disease
Interventions
STA-5326
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Tucson, Arizona • Anaheim, California • North Miami Beach, Florida + 12 more
Conditions
Usher Syndrome, Retinitis Pigmentosa
Interventions
SAR421869
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Completed No phase listed Observational Accepts healthy volunteers Results available

Wide Frequency Band Test of Hearing in Veterans

NCT02019888
Conditions
Hearing Loss, Sensorineural, Hearing Loss, Conductive, Hearing Loss, Mixed Conductive-Sensorineural, Otosclerosis, Tympanic Membrane Perforation, Otitis Media With Effusion, Cholesteatoma
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 89 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Mountain Home, Tennessee
Conditions
Diabetes Mellitus, Type 2
Interventions
Lispro Mixture Therapy, Glargine Basal-Bolus Therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 41 more
Conditions
Migraine
Interventions
Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
109
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more